

## GI Histology Report

Patient Name  
**Johnson, Thomas F.**

Date of Birth (Age)  
**01/01/1960 (59)**

EMR # **12345**

Patient Phone  
**888.555.1212**

Referring Physician

ICD Code(s)  
**K21.9, R13.10, K31.7, C15.9**

Accession Number  
**QS19-00001**

Requesting Facility  
**ABC GI Specialists**

Requesting Physician  
**Joseph Smith, M.D.**

Referring Physician Fax #

Clinical Information

**Patient History Of : Dysphagia.  
Symptoms : GERD**

Procedure Date  
**01/01/2019**

Received Date  
**01/01/2019**

Report Date  
**01/02/2019**


Lab Case #  
**SP19-00001**



Quantum Pathology, LLC  
303 Bear Hill Road, 2nd Floor  
Waltham, MA 02451  
Phone: 781.373.1689 Fax: 781.373.2078


CLIA#: 22D2081781  
Medical Director: Lindsay B. Hardy, M.D.

### Diagnostic Anatomic Map




A. Stomach, Body, Corpus

B. Esophagus, Stricture



B. Invasive adenocarcinoma.



B. Invasive adenocarcinoma.

### Diagnosis & Interpretation

#### A. Stomach, Body, Corpus, Polyp, Snare Biopsy Fundic gland polyp.

*The biopsy shows oxyntic (fundic) type mucosa with cyst formation. Fundic gland polyps causes include proton pump inhibitor therapy atrophic gastritis and rare conditions such as ZE syndrome.*

#### B. Esophagus, Stricture, Biopsies Adenocarcinoma

- Moderately differentiated.
- Her2-neu Immunoperoxidase stains are positive.

### Gross Description

A. Stomach, Body, Corpus, Polyp, Snare Biopsy - Received in formalin with the patient's name labeled "Corpus Polyp" consists of multiple fragments of tan-pink soft tissue measuring 0.8 x 0.4cm in aggregate. Totally submitted in 1 cassette.

B. Esophagus, Stricture, Biopsies - Received in formalin with the patient's name labeled "Esophagus, Stricture" consists of multiple fragments of tan-pink soft tissue measuring 1.0 x 0.7cm in aggregate. Totally submitted in 1 cassette.

Due to loss of elastic tension and to formalin shrinkage, the measurements in the laboratory description may be less than those taken at the time of surgical removal.

Dr. May Azar  
Final Report Electronically signed on 01/02/2019 at 12:00 PM

The accuracy and adequacy of immunohistochemistry controls have been confirmed upon review.

These Immunohistochemical tests and their performance characteristics are determined by Quantum Pathology LLC, 303 Bear Hill Rd Waltham, MA 02451. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA) as such approval is not required. These tests are permitted for clinical purposes and should not be regarded as purely investigational or for research. Quantum Pathology LLC is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.